Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Abbott to update CardioMEMS to allow patients to track pulmonary artery pressure

5 October 2026 · By · Wire by Fusion42

Published

5 October 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at massdevice.com →

◆ Verified

Fusion42 · 5 October 2026 · Fusion42 review

Abbott received FDA approval for an update to its CardioMEMS heart failure monitoring platform that enables patients to track their pulmonary artery pressure via a smartphone app and receive personalized medication updates.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 5 Oct 2026 and 7 Oct 2026.

◆ ◆ The Wire takeaway

You can now build solutions that empower heart failure patients with direct access to their condition data and personalised care adjustments, shifting some clinical control to patient hands and opening paths for apps integrating real-time treatment feedback.

◆ Coverage

2 sources · first reported 5 Oct 2026 · latest 7 Oct 2026

◆ Related on Wire

◆ Topics

Medtechcardiomemsheart-failurepatient-monitoringfda-approvalmedtech